AEON Biopharma, Inc. — Audit Report / Information 2021

Feb 26, 2021

8-K/A 1 tm218149d1_8ka.htm FORM 8-K/A

Field: Rule-Page

Field: /Rule-Page

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Field: Rule-Page

Field: /Rule-Page

FORM 8-K/A

Field: Rule-Page

Field: /Rule-Page

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 11, 2021

Field: Rule-Page

Field: /Rule-Page

PRIVETERRA ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

Field: Rule-Page

Field: /Rule-Page

Delaware	001-40021	85-3940478
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)
	300 SE 2 nd Street, Suite 600
	Fort Lauderdale, Florida 33301
	(Address of principal executive offices, including zip code)

(754) 220-9229

Registrant’s telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report)

Field: Rule-Page

Field: /Rule-Page

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title
of each class | Trading
Symbol(s) | Name
of each exchange on which registered |
| --- | --- | --- |
| Units, each consisting of one share of Class A common stock and one-third of one redeemable warrant | PMGMU | The Nasdaq Stock Market LLC |
| Class A common stock, par value $0.0001 per share | PMGM | The Nasdaq Stock Market LLC |
| Warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share | PMGMW | The Nasdaq Stock Market LLC |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Introductory Note

This Form 8-K/A is being filed with respect to the Form 8-K filed by Priveterra Acquisition Corp. (the “Company”) on February 18, 2021 (the “Form 8-K”) for the purpose of amending Exhibit 99.1 in Item 9.01 to include the Report of Independent Registered Public Accounting Firm. Except for the changes to the exhibit in Item 9.01, no other changes have been made to the Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Audited Balance Sheet

Field: Page; Sequence: 2

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 26, 2021
By:	/s/ Robert Palmisano
Name:	Robert Palmisano
Title:	Chairman and Chief Executive Officer

Field: Page; Sequence: 3; Options: Last

Field: /Page